Fenbendazole (BED, pronounced FEND) is an antiparasitic medication used to treat parasites in humans and animals. It is also being investigated as a cancer treatment. A man from Michigan named Joe Tippens has been using a combination of fenbendazole, curcumin and CBD to cure his cancer and has seen great success.
Several studies have shown that anthelmintic drugs can kill cancer cells. However, turning these animal anthelmintics into human medications has been challenging.
The anthelmintic drug fenbendazole is used to treat nematode parasitism in both small and large animals. When fenbendazole is administered to livestock, it can leave residues in edible tissues that could potentially expose human consumers to fenbendazole sulfone residues. We developed a model to estimate the amount of pheasant tissue with fenbendazole sulfone contaminant that would have to be consumed to result in observed adverse effects (Equation 1). We used both deterministic and stochastic approaches to consider diverse food safety adverse outcomes (repeat-dose toxicity, reproductive toxicity, teratogenicity, and carcinogenicity) and established tolerance and maximum residue limit values for different edible tissues and matrixes.
To test the effect of fenbendazole on EMT6 cancer cell growth, we exposed the cells to 2 and 24 h treatments with varying concentrations of fenbendazole. Survival was monitored using a rigorous colony formation assay. Regardless of the concentration of fenbendazole, cell numbers in monolayer cultures decreased as treatments progressed. Severe hypoxia increased the sensitivity of the cells to fenbendazole, resulting in significantly lower yield-corrected surviving fractions. fenbendazole for humans